Gastroenterology

  • Home
  • Gastroenterology
Headache Relief Shampoo Voted #1 Best New Product in 2019

Dr. D’s Medicated Headache Relief Shampoo is now available. This medicated shampoo will help alleviate headaches simply by soaking it on your head. Finding relief from minor to severe headaches shouldn’t always involve reaching for a bottle of pills. Dr. D is here to give you another option. Our proprietary formula will leave your head feeling better.

BUY NOW! http://headachereliefshampoo.com/product/headache-relief-shampoo/

January 1, 2019 / by / in
A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
Conditions:   Eosinophilic Gastritis;   Eosinophilic Duodenitis
Interventions:   Drug: antolimab (AK002);   Other: Placebo
Sponsor:   Allakos, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 27, 2020 / by / in
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies
Conditions:   Ovarian Epithelial Cancer;   Gastric Adenocarcinoma;   Pancreas Adenocarcinoma;   Triple Negative Breast Cancer;   Bladder Cancer
Intervention:   Drug: SKB264
Sponsor:   Klus Pharma Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 27, 2020 / by / in
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
Condition:   Adv Solid Malig – H&N SCC, ATM Pro / Def NSCLC, Gastric & Breast Cancer
Interventions:   Drug: Administration of ceralasertib in combination with carboplatin;   Drug: Administration of ceralasertib;   Drug: Administration of ceralasertib in combination with olaparib;   Drug: Administation of ceralasertib in combination with durvalumab
Sponsor:   AstraZeneca
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 25, 2020 / by / in
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
Conditions:   Clinical Stage IV Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IV Gastric Cancer AJCC v8;   Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IVB Gastric Cancer AJCC v8;   Metastatic Esophageal Adenocarcinoma;   Metastatic Gastric Adenocarcinoma;   Oligometastatic Esophageal Adenocarcinoma;   Oligometastatic Gastric Adenocarcinoma;   Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IV Gastric Cancer AJCC v8;   Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
Interventions:   Drug: Capecitabine;   Drug: Fluorouracil;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Radiation: Radiation Therapy
Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 20, 2020 / by / in
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Conditions:   Acute Myeloid Leukemia;   Brain Glioblastoma;   Estrogen Receptor Negative;   Extensive Stage Small Cell Lung Carcinoma;   Head and Neck Carcinoma;   HER2/Neu Negative;   Hormone-Resistant Prostate Cancer;   Limited Stage Small Cell Lung Carcinoma;   Myelodysplastic Syndrome;   Progesterone Receptor Negative;   Progressive Disease;   Recurrent Carcinoma;   Stage II Pancreatic Cancer;   Stage II Rectal Cancer;   Stage IIA Pancreatic Cancer;   Stage IIA Rectal Cancer;   Stage IIB Pancreatic Cancer;   Stage IIB Rectal Cancer;   Stage IIC Rectal Cancer;   Stage III Colon Cancer;   Stage III Esophageal Cancer;   Stage III Gastric Cancer;   Stage III Non-Small Cell Lung Cancer;   Stage III Ovarian Cancer;   Stage III Pancreatic Cancer;   Stage III Rectal Cancer;   Stage III Skin Melanoma;   Stage IIIA Colon Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Rectal Cancer;   Stage IIIA Skin Melanoma;   Stage IIIB Colon Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Rectal Cancer;   Stage IIIB Skin Melanoma;   Stage IIIC Colon Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Rectal Cancer;   Stage IIIC Skin Melanoma;   Stage IV Bladder Cancer;   Stage IV Bone Sarcoma;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Ovarian Cancer;   Stage IV Pancreatic Cancer;   Stage IV Rectal Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma;   Stage IV Soft Tissue Sarcoma;   Stage IVA Bone Sarcoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Bone Sarcoma;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Triple-Negative Breast Carcinoma
Interventions:   Other: Best Practice;   Other: Laboratory Biomarker Analysis;   Procedure: Supportive Care;   Other: Survey Administration
Sponsor:   Stanford University
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 18, 2020 / by / in
A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Condition:   Locally Advanced or Metastatic Malignant Solid Tumors
Intervention:   Drug: enfortumab vedotin
Sponsors:   Astellas Pharma Global Development, Inc.;   Seattle Genetics, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 17, 2020 / by / in
A Randomized, Pilot Study Comparing Cost Effectiveness on Two Commercially Available Gastric Feeding Tubes
Condition:   Long Term Enteral Tube Feeding
Interventions:   Device: Capsule Dome G-Tube;   Device: Balloon Bolus feeding tube
Sponsor:   Ohio State University
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 17, 2020 / by / in
How Gas-Filled Intragastric Balloons Affect Hunger, Hunger Hormones, and Gastric Emptying Compared to Meal Replacements
Condition:   Obesity
Interventions:   Device: GF-IGB: Obalon Balloon;   Dietary Supplement: Medically Supervised Meal Replacement Program: My New Weigh
Sponsor:   University of Colorado, Denver
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 14, 2020 / by / in
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
Conditions:   Chronic Pancreatitis;   Inflammatory Bowel Diseases;   Hepatitis;   NASH – Nonalcoholic Steatohepatitis;   Acute Pancreatitis;   Rheumatoid Arthritis;   Diabetes Mellitus;   Dyslipidemias;   Multiple Sclerosis;   Irritable Bowel Syndrome;   Chronic Pain;   Chronic Disease;   Chronic Kidney Diseases;   Crohn Disease;   Celiac Disease;   Biliary Cirrhosis;   Bile Acid Synthesis Defect;   Gastritis;   Cholecystitis;   Cholelithiases;   IPMN;   Cyst Pancreas;   Cystic Fibrosis;   Pancreatic Exocrine Insufficiency;   Diarrhea Chronic;   Constipation – Functional;   Constipation Chronic Idiopathic
Interventions:   Other: venipuncture;   Behavioral: Questionnaires;   Other: Additional Sample Collections
Sponsor:   University of Pittsburgh
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 14, 2020 / by / in
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Condition:   Gastro-enteropancreatic Neuroendocrine Tumor
Interventions:   Drug: Lutathera;   Drug: long-acting octreotide;   Drug: high dose long-acting octreotide
Sponsor:   Advanced Accelerator Applications
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 13, 2020 / by / in